Celularity (CELU) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Celularity (CELU) has outperformed Psyence Biomedical (PBM) over the past year, losing 73.5% versus a loss of 94.9%. Psyence Biomedical is the larger company by market cap ($15.8 million vs $15.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELU | PBM |
|---|---|---|
| Share price | $0.463 | $2.97 |
| Market cap | $15.02M | $15.80M |
| 1-day change | -1.05% | +3.85% |
| YTD return | -58.29% | -89.90% |
| 1-year return | -73.54% | -94.90% |
| 5-year return | -99.31% | — |
| EPS (TTM) | $-1.69 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $26.55M | — |
| Revenue growth (YoY) | -51.03% | — |
| Net income (latest FY) | $-91.72M | $1.01M |
| Gross margin | 24.39% | — |
| Operating margin | -230.92% | — |
| Net margin | -345.45% | — |
| 52-week high | $2.55 | $73.44 |
| 52-week low | $0.42 | $1.92 |
| Distance from 52-week high | -81.84% | -95.96% |
| Average volume | 3.95M | 61.93K |
| Shares outstanding | 32.45M | 5.32M |
| Employees | 115 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELU has outperformed PBM by 21.4 percentage points over the past year.
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
CELU vs PBM FAQ
Which is bigger, Celularity or Psyence Biomedical?
Psyence Biomedical (PBM) is larger, with a market capitalization of $15.80M compared with $15.02M for Celularity (CELU).
Which stock has performed better over the past year, CELU or PBM?
CELU returned -73.54% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Celularity and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.